Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.
Gefitinib, a selective inhibitor of epidermal growth factor receptor tyrosine kinase is an effective agent used in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Adverse drug reactions were frequently observed in the skin, gastrointestinal tract, and liver, but they were generally mild in severity and reversible. Therefore, gefitinib has been regarded as a relatively safe agent. As a serious adverse effect, however, acute lung injury has been reported. The present report describes a patient with NSCLC who developed bilateral subdural hemorrhage as a possible adverse drug reaction after gefitinib therapy. We expect that this case may provide a reference for clinicians being involved in the treatment with gefitinib.
Kim
Jung Han
JH
Department of Internal Medicine, Hallym Medical Center, Hallym University College of Medicine, Seoul, Republic of Korea. harricil@hotmail.com
Kim
Hyeong Su
HS
Choi
Jong Soo
JS
Lee
Kyung Min
KM
Shin
Young Chul
YC
Ahn
Byung Moo
BM
Choi
Dae Ro
DR
Kwon
Jung Hye
JH
Park
Sarah
S
Kim
Ho Young
HY
Jung
Joo Young
JY
Kim
Hyo Jung
HJ
Song
Hun Ho
HH
Zang
Dae Young
DY
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D000077156:Gefitinib; D006408:Hematoma, Subdural / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib